title: The use of salt-inducible kinase inhibitors to treat autoimmune and inflammatory diseases: evaluation of WO2013136070.
abstract: Novel methods for the treatment of inflammatory and autoimmune diseases comprising the administration of salt-inducible kinase inhibitors are claimed. One novel inhibitor (HG-9-91-01) and the use of 2,4-diaminopyrimidine and 2,6-diaminopyrimidine derivatives are claimed. The use of such inhibitors upregulates the level of the anti-inflammatory cytokine IL-10 in macrophages.
authors.affiliation: Norman Consulting , 18 Pink Lane, Burnham, SL1 8JW , UK peter.norman2@btinternet.com.
authors.forename: Peter
authors.initials: P
authors.lastname: Norman
mesh_terms: D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000201:enzymology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000201:enzymology; D016753:Interleukin-10 / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D010330:Patents as Topic; D010671:Phenylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D004791:Enzyme Inhibitors; C577044:HG-9-91-01; D010671:Phenylurea Compounds; D011743:Pyrimidines; D016753:Interleukin-10; C017205:2,4-diaminopyrimidine; D017346:Protein Serine-Threonine Kinases; C509080:SIK1 protein, human
keywords: IL-10; arthritis; inflammation; macrophage; salt-inducible kinase 1